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Previewschanges in global methylation. This is re-
flected in the lack of changes in the differ-
entiation pattern of CNS stem cells and
failure of these mice to show evidence of
glioma formation even with age.
These mouse models serve as an
important step in modeling oncogenic
IDH alleles and will undoubtedly serve as
the basis for studies combining onco-
genic IDH alleles with other mutations
known to co-occur with IDH1/IDH2muta-
tions in AML, glioma, and other malignan-
cies. These results also raise fundamental
biochemical questions as to whether spe-
cific enzymes are differentially inhibited
by 2HG in a tissue-specific manner, and
which of the many enzymes inhibited by
2HG are essential for transformation. In
addition, further work is needed to bring
greater resolution as to how epigenetic
repatterning at key genes contributes
to oncogenic transformation. Taken
together, these studies demonstrate that
IDH1/IDH2mutations will have pleiotropic
effects in different contexts that contri-bute to transformation in different tumor
types. Moreover, the development of
these models provides an avenue for
preclinical testing of IDH1/IDH2 inhibitors,
such that we learn whether this repre-
sents a potential therapy for the subset
of patients with neomorphic IDH disease
alleles.REFERENCES
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Cancer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regarding
antigen selection, strategy for immune stimulation, patient stratification, andmonitoring of elicited response.
A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into
these central issues.Recent clinical successes have validated
the long-standing idea that therapeutic
manipulation of endogenous immunity
may achieve meaningful anti-tumor ef-
fects (Mellman et al., 2011). Perhaps the
most compelling evidence marshaled to
date derive from studies of blocking
monoclonal antibodies against key nega-
tive immune regulatory molecules,
such as cytotoxic T lymphocyte-associ-
ated antigen-4 and programmed death-1,
which achieve durable tumor regressions
and/or disease control in several typesof malignancies. These therapeutic ap-
proaches are limited in selectivity for
amplifying anti-tumor immune responses,
however, and thereby sometimesprovoke
serious inflammatory reactions in normal
tissues.
Compared to targeting immune regula-
tory pathways, cancer vaccines offer
a stronger potential for focusing immune
reactions toward tumor-specific and
tumor-associated antigens, but the clin-
ical impact of these strategies thus far
has been more modest, highlighting theneed for further optimization (Mellman
et al., 2011). Vaccines aim to load den-
dritic cells (DCs), the professional antigen
presenting cells of the immune system,
with relevant cancer antigens and
stimulate DCs to mature and migrate to
regional lymph nodes, where they may
efficiently prime tumor antigen-specific
T and B lymphocytes. The activated
T cells, particularly cytotoxic CD8+ lym-
phocytes but also CD4+ effectors, may
in turn traffic systemically to metastatic
deposits and thereupon effectuate tumorptember 11, 2012 ª2012 Elsevier Inc. 287
Figure 1. Schema for Developing Tailor-Made Renal Cell Carcinoma Vaccines
Naturally processed peptides derived from highly expressed oncogenic proteins are inoculated in
conjunction with GM-CSF to stimulate tumor-specific CD8+ cytotoxic T cells. The administration of cyclo-
phosphamide prior to vaccination attenuates FoxP3+ Tregs, resulting in more effective and durable anti-
tumor immunity. High levels of apolipoprotein-A1 (APO-A1) and CCL17 are associated with superior
vaccine outcome.
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Previewscell killing. Stimulated B cells may also
differentiate into bone marrow-homing
plasma cells that produce circulating
anti-tumor antibodies.
While the general outline for a cancer
vaccine may be reasonably crafted,
many important details have yet to be
clarified. In this context, the elegant study
of renal cell carcinoma (RCC) vaccines by
Walter et al. (2012) provides valuable
insights into the choice of tumor antigen,
method of immune priming, patient selec-
tion, and immune monitoring.
To identify relevant RCC antigens,
the authors developed a multi-pronged
strategy that combined biochemical,288 Cancer Cell 22, September 11, 2012 ª20genetic, and immunologic techniques.
Because the targets for CD8+ cytotoxic
T cells are short peptides (generated
from any cellular protein) presented in
the context of surfacemajor histocompat-
ibility complex (MHC) class I molecules,
the authors purified these complexes
from a large number of RCC samples
and characterized the associated pep-
tides with mass spectrometry. The ex-
pression profiles of the identified antigens
were then determined, and those gene
products showing the highest levels in
RCC compared to normal kidney and
other healthy tissues were prioritized.
Lastly, the immunogenic potential of the12 Elsevier Inc.peptides was interrogated using in vitro
T cell stimulation assays with peripheral
blood mononuclear cells obtained from
healthy donors and RCC patients.
From this integrated analysis, the
authors selected nine MHC class I
peptides and one MHC class II peptide
(for CD4+ T cells) to serve as the antigenic
components of the vaccine. The targets
included sequences from the hepatocyte
growth factor receptor tyrosine kinase
MET, matrix metalloproteinase 7, cyclin
D1, MUC-1, and two pro-angiogenic sig-
naling molecules, all of which likely con-
tribute to RCC progression. The choice
of multiple, naturally processed pep-
tides derived from proteins with critical
oncogenic functions might reduce the
emergence of antigen-loss tumor variants
under immune selection.
To engender DC responses against
these peptides, Walter and colleagues
co-injected the cytokine granulocyte-
macrophage colony stimulating factor
(GM-CSF) that has been effectively
employed in several earlier vaccine
strategies, including Sipuleucel-T, the
first FDA approved therapeutic cancer
vaccine (Kantoff et al., 2010) (Figure 1).
Consistent with the immunostimulatory
properties of the vaccine formulation,
the investigators observed that 20 of 27
evaluable patients with advanced RCC
generated peptide-specific T cells in the
blood that were detected with flow cy-
tometry using MHC class I/peptide tetra-
mers and functional assays for inter-
feron-gamma production. Patients who
mounted responses to multiple peptides
showed longer survival compared to
those with less intense or no responses,
albeit the trial was not designed to assess
clinical efficacy.
Additional immune analysis revealed
that the induction of CD8+ T cells to
multiple peptide antigens was associated
with lower numbers of FoxP3 expressing
regulatory T cells (Tregs) at the time
of study entry. This finding is consistent
with other data indicating that Tregs
negatively regulate the generation of
anti-tumor cytotoxic T cells, likely reflect-
ing their central role in maintaining im-
mune tolerance (Josefowicz et al., 2012).
Furthermore, recent work has also estab-
lished the ability of GM-CSF to stimulate
not only CD8+ T cells, but Tregs as well,
a feature that might limit vaccine potency
(Jinushi et al., 2007).
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colleagues elected to administer a single
dose of cyclophosphamide prior to the
peptides/GM-CSF inoculation in an effort
to attenuate Treg responses. Earlier work
in murine models and small clinical trials
illustrated that low doses of cyclophos-
phamide, which do not mediate a direct
anti-tumor effect, might decrease Treg
numbers (Le and Jaffee, 2012). To
examine this possibility rigorously, the
authors performed a Phase II trial in 68
advanced RCC patients who were ran-
domized 1:1 to receive either the vaccine
alone or a dose of cyclophosphamide
prior to the first vaccine (a total of 17
vaccines were administered over several
months to both groups). Indeed, cyclo-
phosphamide reduced the numbers of
circulating Tregs by approximately 20%,
and this decrease was primarily in
the subset of proliferating Tregs. In con-
trast, cyclophosphamide did not impact
other lymphocyte populations analyzed,
and patients who received only the
vaccine did not manifest changes in
Treg numbers.
Cyclophosphamide did not alter the
frequency of patients who generated
peptide-specific CD8+ T cells, but the im-
mune responders in this group achieved
longer survival compared to immune
responders who did not receive cyclo-
phosphamide. Patients who failed to
mount T cell responses displayed compa-
rable survival regardless of cyclophos-
phamide treatment. Although the number
of patients studied was relatively small,
these results suggest that cyclophospha-
mide may modulate particular character-
istics of vaccine responses that lead to
more durable disease control. In accor-
dance with this idea, a recent clinical trial
in breast cancer that employed anti-
CD25 blocking monoclonal antibodies to
decrease Tregs in combination with pep-tide vaccines and GM-CSF similarly re-
vealed augmented T cell responses and
survival compared to earlier studies of
vaccines alone (Rech et al., 2012).
To learn more about the factors that
influence vaccine outcome, Walter and
colleagues performed detailed immune
profiling of patients prior to treatment.
Among several cell types implicated in
immune suppression (Gabrilovich et al.,
2012), the authors found that increases
in two myeloid cell populations (CD14+
HLA-DR-/lo and CD11b+CD14CD15+)
were associated with inferior overall
survival. Moreover, among 300 soluble
factors measured in the sera, high levels
of apolipoprotein A1, a major constituent
of high-density lipoprotein complexes,
and the chemokine CCL17 were predic-
tive for prolonged survival after vaccina-
tion. While the precise role of these
proteins in immunization requires further
study, one attractive possibility focuses
on natural killer T (NKT) cells, a small pop-
ulation of lymphocytes that functions at
the interface of innate and adaptive tumor
immunity. NKT cells recognize lipid anti-
gens and may activate DCs to stimulate
CD8+ cytotoxic T cells via a mechanism
that involves CCL17 (Semmling et al.,
2010).
Based on these two informative
clinical trials, Walter and colleagues have
launched a large Phase III trial to delin-
eate the clinical efficacy of the pep-
tide/GM-CSF/cyclophosphamide vaccine
(IMA901) administered as a component of
initial therapy for advanced RCC (http://
clinicaltrials.gov number NCT01265901).
Patients are randomized to sunitinib alone
(the standard of care) or sunitinib plus
IMA901,withoverall survival as theprimary
endpoint. Prior work has suggested that
sunitinib might be immunostimulatory,
perhaps through diminishing Treg and
myeloid suppressive cell numbers via inhi-Cancer Cell 22, Sebition of vascular endothelial growth factor
receptor signaling (Gabrilovich et al.,
2012). This integration of vaccines and tar-
geted therapy represents a very promising
approach to cancer treatment, and is likely
to be soon followed with the addition of
immunomodulatory antibodies (Vanne-
man and Dranoff, 2012). Overall, the care-
ful clinical investigations of Walter and
associates havehelped toprovide a strong
framework for exploring innovative combi-
natorial therapies.REFERENCES
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